Breaking News
July 17, 2018 - Long-term survival worse for black survivors of in-hospital cardiac arrest
July 17, 2018 - Stanford data analyst’s childhood inspires his research: A Q&A
July 17, 2018 - Preventability of hospital readmissions changes over time, study reveals
July 17, 2018 - Nursing notes can help predict if ICU patients will survive
July 17, 2018 - Okayama University research could improve prognosis of diabetic kidney disease
July 17, 2018 - Study identifies new genes linked to heart function and development
July 17, 2018 - NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology
July 17, 2018 - Improved methods to measure enterococci concentrations in recreational water
July 17, 2018 - White adolescent boys experiencing early puberty have high risk for substance use
July 17, 2018 - Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
July 17, 2018 - Roots of leukemia reveal possibility of predicting people at risk
July 17, 2018 - Summer med program embraces low-income students’ potential
July 17, 2018 - New research lays foundation to create standards for RNA sequencing
July 17, 2018 - CRISPR/Cas9 gene editing can cause greater genetic damage than previously thought
July 17, 2018 - Democrats rally against threats to the ACA to block Trump’s Supreme Court nominee
July 17, 2018 - Staggering prices slow insurers’ coverage of CAR-T cancer therapy
July 17, 2018 - How proteins involved in neurodegeneration enter cells
July 17, 2018 - New super-resolution ‘nanoscope’ provides insight into progression of Alzheimer’s disease
July 17, 2018 - FDA Advisory Committee Endorses the Effectiveness and Safety of Single-Dose Tafenoquine for the Radical Cure of P. vivax Malaria
July 17, 2018 - Uncovering the evolutionary history of IBD-associated colorectal cancer
July 17, 2018 - Is nutrition research dependable? Stanford’s John Ioannidis weighs in
July 17, 2018 - New machine learning framework predicts effects of genetic mutations in ‘dark matter’ regions
July 17, 2018 - Plant-based products fail to have positive impact on blood pressure during clinical studies
July 17, 2018 - Electronic system to speed up facial pain diagnosis may improve quality of life and save money
July 17, 2018 - Study delves into the role played by Protein Kinase C in synaptic plasticity
July 17, 2018 - Women Often Unaware of Their Hospital’s Religious Affiliation
July 17, 2018 - New AASM guideline recommends use of actigraphy for sleep disorders
July 17, 2018 - CRISPR editing reduces repetitive behavior in mice with a form of autism
July 17, 2018 - Scientists use magnets to detect cancer
July 17, 2018 - Microfluidic chip to detect sepsis proves successful in clinical study
July 17, 2018 - Research provides better understanding of mechanisms underlying memory storage
July 17, 2018 - A Multi-Modal Approach for the Early Detection of Breast Cancer
July 17, 2018 - Mailing colorectal cancer tests to patients increases screening rates, report researchers
July 17, 2018 - Scientists find possible sources of medicinal and antimicrobial drugs
July 17, 2018 - Molecules formed when the body metabolizes omega-3 fatty acids may inhibit cancer
July 17, 2018 - Efficient communication between hospitals improves patient safety and reduces mortality
July 17, 2018 - Study highlights potential of fetal gene therapy to prevent lethal neurodegenerative disease
July 17, 2018 - For Americans, in Science They Trust
July 17, 2018 - Combating HIV/AIDS | NIH MedlinePlus the Magazine
July 17, 2018 - Study shows minorities widely underrepresented in autism diagnoses
July 17, 2018 - Multigene testing replacing BRCA tests for breast cancer risk | News Center
July 17, 2018 - Pre-clinical pilot study shows promising results of ‘concussion pill’
July 17, 2018 - Researchers reduce size of tumors in mice by artificially activating the brain’s reward system
July 17, 2018 - New study documents symptoms of people before they acquire multiple sclerosis
July 17, 2018 - Researchers discover why CRISPR gene editing sometimes fails
July 17, 2018 - New finding may hold key to better understand the complexities of neurological disorders
July 17, 2018 - The Current issue of “The view from here” is concerned with Novel Targets.
July 17, 2018 - Fighting the Flu with a Universal Vaccine
July 17, 2018 - Key social reward circuit in the brain impaired in kids with autism | News Center
July 17, 2018 - Insight into causes, types and treatment of aphasia
July 16, 2018 - Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
July 16, 2018 - NSAIDs shown to have causal role in cardiovascular risk of patients with osteoarthritis
July 16, 2018 - PET scan tracer predicts success of cancer ‘vaccine’ | News Center
July 16, 2018 - Parents struggle with what to do when their child has headache, shows study
July 16, 2018 - Outrageous or overblown? HHS announces another round of ACA navigator funding cuts
July 16, 2018 - Weight loss surgery may impact individual’s risk of developing cancer, shows study
July 16, 2018 - Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
July 16, 2018 - Restoring epigenetic balance reinstates memory in flies with Alzheimer’s disease symptoms
July 16, 2018 - Magnetized wire could be used to detect cancer in people | News Center
July 16, 2018 - Non-surgical management found to be feasible option for penetrating kidney trauma
July 16, 2018 - California clinic screens asylum seekers for honesty
July 16, 2018 - FDA Approves Xtandi (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
July 16, 2018 - Can nanotechnology help treat Alzheimer’s?
July 16, 2018 - Researchers identify protein essential for making stem cells | News Center
July 16, 2018 - Severe childhood infections linked with lower school achievement in adolescence
July 16, 2018 - Radiologist discusses causes, treatments of varicose veins
July 16, 2018 - Researchers develop nanostructured surface to accelerate wound healing after dental implants
July 16, 2018 - New non-invasive procedure to reposition kidney stones could benefit astronauts
July 16, 2018 - Attending Surgeon Influences Genetic Testing in Breast Cancer
July 16, 2018 - Medical doctors with addictions fear professional repercussions if they seek treatment
July 16, 2018 - 5 Questions: John Ioannidis calls for more rigorous nutrition research | News Center
July 16, 2018 - University of Illinois buys 3D-Bioplotter for regenerative biology, tissue engineering research
July 16, 2018 - Charité’s researchers integrate open-source platform into the ‘Human Brain Project’
July 16, 2018 - SUSU scientists develop rehabilitation device for people with lower limbs injuries
July 16, 2018 - Researchers find definite increase in scooter-related injuries
July 16, 2018 - Researchers solve mystery of final blood group system
July 16, 2018 - Researchers develop near-infrared fluorophores-based PDT to cure cancer with less side effects
July 16, 2018 - Traumatic brain injury biomarker could help predict patient prognosis
July 16, 2018 - Researchers to investigate role of hormones in mosquito’s ability to use human blood for egg production
July 16, 2018 - AHA: Doctor Makes Lifesaving House Call in His Own Home

FDA Approves Rydapt (midostaurin) for FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis

image_pdfDownload PDFimage_print

FDA Approves Rydapt (midostaurin) for FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis

April 28, 2017 — The U.S. Meals and Drug Management lately authorized Rydapt (midostaurin) for the remedy of grownup sufferers with newly identified acute myeloid leukemia (AML) who’ve a selected genetic mutation referred to as FLT3, together with chemotherapy. The drug is authorized to be used with a spouse diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to locate the FLT3 mutation in sufferers with AML.

AML is a unexpectedly progressing most cancers that bureaucracy within the bone marrow and ends up in an larger selection of white blood cells within the bloodstream. The Nationwide Most cancers Institute estimated that roughly 19,930 other people can be identified with AML in 2016 and 10,430 had been projected to die of the illness.

“Rydapt is the primary centered remedy to regard sufferers with AML, together with chemotherapy,” stated Richard Pazdur, M.D., appearing director of the Place of business of Hematology and Oncology Merchandise within the FDA’s Heart for Drug Analysis and Analysis and director of the FDA’s Oncology Heart of Excellence. “The facility to locate the gene mutation with a diagnostic take a look at manner medical doctors can establish particular sufferers who might have the benefit of this remedy.”

Rydapt is a kinase inhibitor that works by way of blockading a number of enzymes that advertise mobile expansion. If the FLT3 mutation is detected in blood or bone marrow samples the usage of the LeukoStrat CDx FLT3 Mutation Assay, the affected person is also eligible for remedy with Rydapt together with chemotherapy.

The security and efficacy of Rydapt for sufferers with AML had been studied in a randomized trial of 717 sufferers who had no longer been handled in the past for AML. Within the trial, sufferers who won Rydapt together with chemotherapy lived longer than sufferers who won chemotherapy by myself, even if a selected median survival price may just no longer be reliably estimated. As well as, sufferers who won Rydapt together with chemotherapy within the trial went longer (median eight.2 months) with out sure headaches (failure to reach whole remission inside 60 days of beginning remedy, development of leukemia or loss of life) than sufferers who won chemotherapy by myself (median 3 months).

Commonplace uncomfortable side effects of Rydapt in sufferers with AML come with low ranges of white blood cells with fever (febrile neutropenia), nausea, irritation of the mucous membranes (mucositis), vomiting, headache, spots at the pores and skin because of bleeding (petechiae), musculoskeletal ache, nosebleeds (epistaxis), device-related an infection, top blood sugar (hyperglycemia) and higher respiration tract an infection. Rydapt must no longer be utilized in sufferers with allergy to midostaurin or different elements in Rydapt. Girls who’re pregnant or breastfeeding must no longer take Rydapt as a result of it will reason hurt to a creating fetus or a new child child. Sufferers who revel in indicators or signs of lung injury (pulmonary toxicity) must forestall the usage of Rydapt.

Rydapt used to be additionally authorized lately for adults with sure varieties of uncommon blood problems (competitive systemic mastocytosis, systemic mastocytosis with related hematological neoplasm or mast mobile leukemia). Commonplace uncomfortable side effects of Rydapt in those sufferers come with nausea, vomiting, diarrhea, swelling (edema), musculoskeletal ache, belly ache, fatigue, higher respiration tract an infection, constipation, fever, headache and shortness of breath.

The FDA granted this utility Precedence Evaluation, Rapid Monitor (for the mastocytosis indication) and Step forward Treatment (for the AML indication) designations.

The FDA granted the approval of Rydapt to Novartis Prescribed drugs Company. The FDA granted the approval of the LeukoStrat CDx FLT3 Mutation Assay to Invivoscribe Applied sciences Inc.

Supply: FDA

Posted: April 2017

Rydapt (midostaurin) FDA Approval Historical past

View feedback

Tagged with:

About author

Related Articles